亚虹医药：APL-2401完成I期临床试验首例受试者入组

Core Viewpoint - The company has announced the completion of the first patient enrollment in a Phase I clinical trial for its self-developed APL-2401, a dual-target small molecule inhibitor for FGFR2/3, aimed at providing new treatment options for patients with advanced solid tumors [1] Group 1 - APL-2401 is a highly selective small molecule inhibitor targeting fibroblast growth factor receptors 2 and 3 (FGFR2/3) [1] - The clinical trial focuses on patients with advanced solid tumors driven by FGFR2/3 [1] - The development of APL-2401 represents a potential new therapeutic choice for this patient population [1]